US StockDetailed Quotes

Provided by Tiger Trade Technology Pte. Ltd.

F/m Emerald Life Sciences Innovation ETF

48.06

+0.57331.21%

Post-market: 47.11-0.9528-1.98%19:30 EDT

Volume:5K

Turnover:221.35K

Market Cap:132.51M

PE:- -

High:48.19

Open:48.00

Low:47.87

Close:47.49

52wk High:48.78

52wk Low:27.34

Shares:2.76M

Float Shares:2.76M

Volume Ratio:1.31

T/O Rate:0.17%

Dividend:- -

Dividend Rate:- -

ROE:--

ROA:--

PB:--

PE(LYR):- -

Loading ...

Overview Company News Filings

Travere Therapeutics (TVTX) Stock Rallies Over 13% After Hours: Here's What Is Going On

Benzinga Earnings

Travere Therapeutics, Inc. : TD Cowen Raises Target Price to $75 from $60

THOMSON REUTERS

Spyre Therapeutics Inc : Jefferies Raises Target Price to $122 from $98

THOMSON REUTERS

Travere Therapeutics, Inc. : Guggenheim Raises Target Price to $75 from $65

THOMSON REUTERS

Wall Street Analysts Are Bullish on Top Healthcare Picks

Spyre Therapeutics Inc Reports Results for the Quarter Ended June 30 - Earnings Summary

Travere Therapeutics Inc Reports Results for the Quarter Ended June 30 - Earnings Summary

Travere Therapeutics Q2 Product Sales Rise on Filspari Demand

Spyre Therapeutics Q2 Loss Narrower than Expected; Sees Trial Readouts in 2026

Travere Q2 FY26 Net Loss Widens to $34.8 Million; Filspari Net Sales Rise 96% Year-over-Year to $141.1 Million

Press Release: Spyre Therapeutics Reports Second Quarter 2026 Financial Results and Provides Corporate Update

Travere Therapeutics Q2 EPS USD -0.37

THOMSON REUTERS

Guardant Health is Maintained at Overweight by Morgan Stanley

Guardant Health (GH) Filed A Shelf Registration To Keep Future Funding Options Open

Simply Wall St.

ClearPoint Neuro reports Q2 EPS (38c), consensus (29c)

Fresenius announces FDA approval of rituximab biosimilar

Analysts Conflicted on These Healthcare Names: Guardant Health (GH) and Cardinal Health (CAH)

Lotus Property Schedules Public Consultation on Library Street Affordable Housing Plan

Guardant Health Shares Climb Following Outlook Raise

RBC Raises Price Target on Guardant Health to $200 From $185, Keeps Outperform Rating

MT Newswires Live

{"basename":"","ssrTDKData":{"titleTemplate":"%s - Tiger Brokers","title":"Tiger Brokers | Global Stocks, Options & Futures Trading App","description":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","keywords":"tiger brokers,tiger trade,tiger brokers singapore,broker online,stock trading in singapore,share trading singapore,brokerage firm singapore,trading app,stock broker singapore,stock trading platforms,trading account","social":{"ogDescription":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.0a0bd8dc.png","ogUrl":"https://www.etasphere.com/stock/LFSC/news?page=7"},"companyName":"Tiger Brokers"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental","symbol":"LFSC","isAnalysisPage":false},"__swrFallback__":{"@#url:\"https://hq.skytigris.cn/stock_info/detail/global\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"LFSC\",,,,,undefined,":{"symbol":"LFSC","market":"US","secType":"STK","nameCN":"F/m Emerald Life Sciences Innovation ETF","latestPrice":48.0628,"timestamp":1787688000000,"preClose":47.4895,"halted":0,"volume":4612,"hourTrading":{"tag":"盘后","latestPrice":47.11,"preClose":48.0628,"latestTime":"19:30 EDT","volume":194,"amount":9205.2812,"timestamp":1787700602165,"change":-0.9528,"changeRate":-0.019824,"amplitude":0.019142},"delay":0,"changeRate":0.012072142263026633,"floatShares":2757035,"shares":2757035,"eps":0,"marketStatus":"Not Yet Opened","change":0.5733,"latestTime":"08-25 16:00:00 EDT","open":48,"high":48.19,"low":47.87,"amount":221346.80604,"amplitude":0.006738,"askPrice":0,"askSize":0,"bidPrice":0,"bidSize":0,"shortable":3,"etf":1,"ttmEps":0,"tradingStatus":0,"nextMarketStatus":{"tag":"Pre-Mkt","tradingStatus":1,"beginTime":1787731200000},"marketStatusCode":0,"adr":0,"exchange":"NASDAQ","adjPreClose":47.4895,"sharesOutstanding":2657035,"nav":47.45,"aum":130821310.75,"bidAskSpread":0,"postHourTrading":{"tag":"盘后","latestPrice":47.11,"preClose":48.0628,"latestTime":"19:30 EDT","volume":194,"amount":9205.2812,"timestamp":1787700602165,"change":-0.9528,"changeRate":-0.019824,"amplitude":0.019142},"volumeRatio":1.311494},"@#url:\"https://hq.skytigris.cn/stock_info/fundamental/all\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"LFSC\",,,,,undefined,":{"symbol":"LFSC","floatShares":2757035,"roa":"--","roe":"--","lyrEps":0,"volumeRatio":1.311494,"shares":2757035,"dividePrice":0,"high":48.19,"amplitude":0.006738,"preClose":47.4895,"low":47.87,"week52Low":27.3402,"pbRate":"--","week52High":48.78,"institutionHeld":0,"latestPrice":48.0628,"eps":0,"divideRate":0,"volume":4612,"delay":0,"ttmEps":0,"open":48,"prevYearClose":36.6147,"prevWeekClose":47.7953,"prevMonthClose":45.55,"prevQuarterClose":45.2033,"fiveDayClose":47.489,"twentyDayClose":45.3952,"sixtyDayClose":39.3901},"@#url:\"https://hq.skytigris.cn/fundamental/corporate_actions/details/LFSC\",params:#limit:5,,,undefined,":[],"@#url:\"https://hq.skytigris.cn/fundamental/dividend/history\",params:#symbol:\"LFSC\",market:\"US\",,,undefined,":[],"@#url:\"https://hq.skytigris.cn/fundamental/estimate/recommendation\",params:#symbol:\"LFSC\",market:\"US\",delay:false,,,undefined,":{},"$inf$@#url:\"https://stock-news.skytigris.cn/v2/news/list\",params:#symbols:\"LFSC\",pageSize:20,pageCount:7,lang_content:\"en\",edition:\"fundamental\",,,undefined,":[{"items":[{"id":"2657516665","title":"Travere Therapeutics (TVTX) Stock Rallies Over 13% After Hours: Here's What Is Going On","url":"https://stock-news.laohu8.com/highlight/detail?id=2657516665","media":"Benzinga Earnings","labels":["express"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2657516665?lang=en_us&edition=fundamental","pubTime":"2026-08-05 15:16","pubTimestamp":1785914176,"startTime":"0","endTime":"0","summary":"Travere Therapeutics shares surged 13.44% after hours as strong revenue growth and FILSPARI sales gains outweighed earnings concerns.","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.benzinga.com/markets/equities/26/08/60938354/travere-therapeutics-shares-surge-after-hours-on-revenue-growth","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"2","news_top_title":null,"news_tag":"express","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LFSC","BK4139","ODDZ","RSI","ODDS","BETZ","TVTX","FFTY","BK4150"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2657977695","title":"Travere Therapeutics, Inc. : TD Cowen Raises Target Price to $75 from $60","url":"https://stock-news.laohu8.com/highlight/detail?id=2657977695","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2657977695?lang=en_us&edition=fundamental","pubTime":"2026-08-05 13:11","pubTimestamp":1785906671,"startTime":"0","endTime":"0","summary":null,"market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260805:nFWN4420C0:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["LFSC","TVTX","BK4139"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2657959733","title":"Spyre Therapeutics Inc : Jefferies Raises Target Price to $122 from $98","url":"https://stock-news.laohu8.com/highlight/detail?id=2657959733","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2657959733?lang=en_us&edition=fundamental","pubTime":"2026-08-05 12:45","pubTimestamp":1785905138,"startTime":"0","endTime":"0","summary":null,"market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260805:nFWN442029:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK4139","SYRE","LFSC"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2657592054","title":"Travere Therapeutics, Inc. : Guggenheim Raises Target Price to $75 from $65","url":"https://stock-news.laohu8.com/highlight/detail?id=2657592054","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2657592054?lang=en_us&edition=fundamental","pubTime":"2026-08-05 12:39","pubTimestamp":1785904752,"startTime":"0","endTime":"0","summary":null,"market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260805:nFWN44207D:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["LFSC","TVTX","BK4139"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2657659121","title":"Wall Street Analysts Are Bullish on Top Healthcare Picks","url":"https://stock-news.laohu8.com/highlight/detail?id=2657659121","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2657659121?lang=en_us&edition=fundamental","pubTime":"2026-08-05 11:00","pubTimestamp":1785898840,"startTime":"0","endTime":"0","summary":"There’s a lot to be optimistic about in the Healthcare sector as 2 analysts just weighed in on Illumina (ILMN) and Travere Therapeutics (TVTX) with...","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/blurbs/wall-street-analysts-are-bullish-on-top-healthcare-picks-blurbs-news-276?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/blurbs/wall-street-analysts-are-bullish-on-top-healthcare-picks-blurbs-news-276?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["BK4534","BK4548","BK4139","BK4588","LFSC","GNOM","BK4121","BK4585","TVTX","ILMN","BK4535","LU0128526141.USD","LU0029874061.USD","GNMX"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2657567255","title":"Spyre Therapeutics Inc Reports Results for the Quarter Ended June 30 - Earnings Summary","url":"https://stock-news.laohu8.com/highlight/detail?id=2657567255","media":"Reuters","labels":["express"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2657567255?lang=en_us&edition=fundamental","pubTime":"2026-08-05 05:21","pubTimestamp":1785878482,"startTime":"0","endTime":"0","summary":"Spyre Therapeutics Inc reports results for the quarter ended June 30 - Earnings SummarySpyre Therapeutics IncSYRE.OQreported a quarterly adjusted loss of 36 cents per share for the quarter ended June ","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260804:nL8N44137O:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"express","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LFSC","SYRE","BK4139"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2657673535","title":"Travere Therapeutics Inc Reports Results for the Quarter Ended June 30 - Earnings Summary","url":"https://stock-news.laohu8.com/highlight/detail?id=2657673535","media":"Reuters","labels":["express"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2657673535?lang=en_us&edition=fundamental","pubTime":"2026-08-05 05:01","pubTimestamp":1785877300,"startTime":"0","endTime":"0","summary":"Travere Therapeutics Inc reports results for the quarter ended June 30 - Earnings SummaryTravere Therapeutics IncTVTX.OQreported quarterly adjusted earnings of 6 cents per share for the quarter ended ","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260804:nL8N44134F:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"express","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["TVTX","LFSC","BK4139"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2657611015","title":"Travere Therapeutics Q2 Product Sales Rise on Filspari Demand","url":"https://stock-news.laohu8.com/highlight/detail?id=2657611015","media":"Reuters","labels":["productRelease","express"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2657611015?lang=en_us&edition=fundamental","pubTime":"2026-08-05 04:15","pubTimestamp":1785874544,"startTime":"0","endTime":"0","summary":"Travere Therapeutics Q2 product sales rise on FILSPARI demandOverviewU.S. biopharma's Q2 net product sales rose 70% yr/yr, driven by FILSPARI growthCompany posted a Q2 net loss after a $40 mln inducem","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260804:nL1N44113R:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease,express","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LFSC","TVTX","BK4585","MEDI","BK4139","RYTM","BK4588","IBRX"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2657561508","title":"Spyre Therapeutics Q2 Loss Narrower than Expected; Sees Trial Readouts in 2026","url":"https://stock-news.laohu8.com/highlight/detail?id=2657561508","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2657561508?lang=en_us&edition=fundamental","pubTime":"2026-08-05 04:14","pubTimestamp":1785874443,"startTime":"0","endTime":"0","summary":"Spyre Therapeutics Q2 loss narrower than expected; sees trial readouts in 2026OverviewUS biotech firm's Q2 net loss and pretax loss were lower than analyst expectationsQ2 results included a $40 mln ga","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260804:nL1N44113Q:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["SYRE","LFSC","MEDI","PVLA","RYTM","DSGN","BK4588","BK4505","BK4585","BK4139","BK4539"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2657656922","title":"Travere Q2 FY26 Net Loss Widens to $34.8 Million; Filspari Net Sales Rise 96% Year-over-Year to $141.1 Million","url":"https://stock-news.laohu8.com/highlight/detail?id=2657656922","media":"Reuters","labels":["express"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2657656922?lang=en_us&edition=fundamental","pubTime":"2026-08-05 04:07","pubTimestamp":1785874058,"startTime":"0","endTime":"0","summary":"Travere Q2 FY26 net loss widens to $34.8 million; FILSPARI net sales rise 96% year-over-year to $141.1 millionTravere posted Q2 GAAP net loss of USD 34.8 million, or USD 0.37 per share, versus a loss ","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260804:nNDL6hCCl9:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"express","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4139","LFSC","TVTX"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2657256955","title":"Press Release: Spyre Therapeutics Reports Second Quarter 2026 Financial Results and Provides Corporate Update","url":"https://stock-news.laohu8.com/highlight/detail?id=2657256955","media":"Dow Jones","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2657256955?lang=en_us&edition=fundamental","pubTime":"2026-08-05 04:02","pubTimestamp":1785873720,"startTime":"0","endTime":"0","summary":"Announced positive topline induction data for SPY001 and SPY002 from Part A of the Phase 2 SKYLINE trial (\"SKYLINE\"), demonstrating best-in-class efficacy potential and a safety profile consistent wit","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["SYRE","LFSC","BK4539","IBD","BK4139","BK4007","LENZ"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2657756677","title":"Travere Therapeutics Q2 EPS USD -0.37","url":"https://stock-news.laohu8.com/highlight/detail?id=2657756677","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2657756677?lang=en_us&edition=fundamental","pubTime":"2026-08-05 04:01","pubTimestamp":1785873662,"startTime":"0","endTime":"0","summary":null,"market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260804:nPLXFF9SQ5:2","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK4139","LFSC","TVTX"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2656556059","title":"Guardant Health is Maintained at Overweight by Morgan Stanley","url":"https://stock-news.laohu8.com/highlight/detail?id=2656556059","media":"Dow Jones","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2656556059?lang=en_us&edition=fundamental","pubTime":"2026-08-04 20:44","pubTimestamp":1785847440,"startTime":"0","endTime":"0","summary":"Ratings actions from Benzinga: https://www.benzinga.com/quote/GH/analyst-ratings","market":"sg","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["PTH","LU0109394709.USD","FFOX","GH","HELX","BK4588","BK4535","GNOM","BK4551","LU0889565916.HKD","LU0320765992.SGD","LFSC","GDOC","EKG","BK4585","GNMX","BK4196"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2656753914","title":"Guardant Health (GH) Filed A Shelf Registration To Keep Future Funding Options Open","url":"https://stock-news.laohu8.com/highlight/detail?id=2656753914","media":"Simply Wall St.","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2656753914?lang=en_us&edition=fundamental","pubTime":"2026-08-04 15:22","pubTimestamp":1785828122,"startTime":"0","endTime":"0","summary":"Guardant Health filed a universal shelf registration statement, allowing it to issue various securities in the future.\nThe filing gives the company flexibility to raise capital through debt, equity, or hybrid instruments as needed.\nThis development could be used to support future financing, potential acquisitions, or balance sheet adjustments.\n\nGuardant Health, listed as NasdaqGS:GH, now has formal flexibility to raise funds through a range of securities. The stock last closed at $158.83 and...","market":"nz","thumbnail":"https://images.simplywall.st/asset/industry/6032000-choice2-main-header/1585186864566","type":0,"news_type":0,"thumbnails":["https://images.simplywall.st/asset/industry/6032000-choice2-main-header/1585186864566"],"rights":{"source":"simplywall_highlight","url":"https://simplywall.st/stocks/us/healthcare/nasdaq-gh/guardant-health/news/guardant-health-gh-filed-a-shelf-registration-to-keep-future","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://simplywall.st/stocks/us/healthcare/nasdaq-gh/guardant-health/news/guardant-health-gh-filed-a-shelf-registration-to-keep-future","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"simplywall_highlight","symbols":["LU0109394709.USD","LU0320765992.SGD","HELX","BK4588","GNOM","LU0889565916.HKD","GH","GNMX","FFOX","EKG","PTH","LFSC","BK4551","BK4535","BK4585","GDOC","BK4196"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2656302838","title":"ClearPoint Neuro reports Q2 EPS (38c), consensus (29c)","url":"https://stock-news.laohu8.com/highlight/detail?id=2656302838","media":"TIPRANKS","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2656302838?lang=en_us&edition=fundamental","pubTime":"2026-08-04 04:40","pubTimestamp":1785789624,"startTime":"0","endTime":"0","summary":"Reports Q2 revenue $10.88M, consensus $12.73M. “Establishing ClearPoint Neuro (CLPT) as the leading neuro cell and gene therapy delivery company ha...","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/the-fly/clearpoint-neuro-reports-q2-eps-38c-consensus-29c-thefly-news?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/the-fly/clearpoint-neuro-reports-q2-eps-38c-consensus-29c-thefly-news?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["BK4585","CNCR","WDNA","GNOM","IBB","IBBQ","IDNA","TBXU","BK4082","CLPT","SYNB","HELX","LFSC","JDOC","BK4588","FBT"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2656304376","title":"Fresenius announces FDA approval of rituximab biosimilar","url":"https://stock-news.laohu8.com/highlight/detail?id=2656304376","media":"TIPRANKS","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2656304376?lang=en_us&edition=fundamental","pubTime":"2026-08-04 04:15","pubTimestamp":1785788150,"startTime":"0","endTime":"0","summary":"Fresenius Kabi, an operating company of Fresenius (FSNUY), announced that the U.S. Food and Drug Administration has approved a rituximab biosimilar...","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/the-fly/fresenius-announces-fda-approval-of-rituximab-biosimilar-thefly-news?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/the-fly/fresenius-announces-fda-approval-of-rituximab-biosimilar-thefly-news?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["BK4588","BBP","FSNUY","BMED","BK4196","LABU","SYNB","GNMX","MRNX","IYH","NVIB","PINK","LFSC","MEDI","GDOC","MRNY","XLVX","RSPH","BK4585","IDNA","FRTY","PSCH","TECB","TBXU","IEIH","IBB"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2656697372","title":"Analysts Conflicted on These Healthcare Names: Guardant Health (GH) and Cardinal Health (CAH)","url":"https://stock-news.laohu8.com/highlight/detail?id=2656697372","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2656697372?lang=en_us&edition=fundamental","pubTime":"2026-08-03 22:00","pubTimestamp":1785765628,"startTime":"0","endTime":"0","summary":"Companies in the Healthcare sector have received a lot of coverage today as analysts weigh in on Guardant Health (GH) and Cardinal Health (CAH). Gu...","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/blurbs/analysts-conflicted-on-these-healthcare-names-guardant-health-gh-and-cardinal-health-cah-blurbs-news?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/blurbs/analysts-conflicted-on-these-healthcare-names-guardant-health-gh-and-cardinal-health-cah-blurbs-news?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["LU0029874061.USD","BK4588","CAH","LU1880398554.USD","LU1267930227.SGD","BK4581","LU0889566641.SGD","BK4196","LABU","GH","GNOM","GNMX","SG9999001440.SGD","LU1983299246.USD","LU0006061336.USD","LU1267930490.SGD","LU0109394709.USD","LU0310799852.SGD","LU1267930813.SGD","LU1571399168.USD","PTH","LFSC","GDOC","XLV","BK4175","LU0889565916.HKD","LU0128525689.USD","LU0052756011.USD","LU0320765992.SGD","LU0162691827.USD","HELX","BK4535","HCSG","EKG","LU0128526141.USD","LU0310800965.SGD","BK4585","FFOX","LU0154236417.USD","LU1880398471.USD","LU0792757196.USD","LU0211328371.USD","XBI","BK4551","BK4137","LU0072461881.USD","LU0211327993.USD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2656375701","title":"Lotus Property Schedules Public Consultation on Library Street Affordable Housing Plan","url":"https://stock-news.laohu8.com/highlight/detail?id=2656375701","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2656375701?lang=en_us&edition=fundamental","pubTime":"2026-08-03 19:44","pubTimestamp":1785757494,"startTime":"0","endTime":"0","summary":"Lotus Property schedules public consultation on Library Street affordable housing planLotus Property scheduled a public consultation for Sept. 15, 2026 on its proposed 170-unit affordable housing sche","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260803:nNDL6px61F:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LU2065171402.SGD","LU2065169927.USD","LU2065170008.USD","LIVN","LFSC","LU2065171311.SGD","BK4082"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2655885398","title":"Guardant Health Shares Climb Following Outlook Raise","url":"https://stock-news.laohu8.com/highlight/detail?id=2655885398","media":"Dow Jones","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2655885398?lang=en_us&edition=fundamental","pubTime":"2026-07-31 23:54","pubTimestamp":1785513240,"startTime":"0","endTime":"0","summary":"Shares of Guardant Health are trading higher after the company raised its full-year revenue outlook and reported higher-than-expected sales during the second quarter.The stock rose 6.1%, to $161.69, o","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4535","LU0889565916.HKD","GNMX","BK4585","PTH","BK4196","HELX","BK4588","LU0109394709.USD","GDOC","GH","EKG","FFOX","GNOM","LFSC","LU0320765992.SGD","BK4551"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2655912361","title":"RBC Raises Price Target on Guardant Health to $200 From $185, Keeps Outperform Rating","url":"https://stock-news.laohu8.com/highlight/detail?id=2655912361","media":"MT Newswires Live","labels":["shareholding","express"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2655912361?lang=en_us&edition=fundamental","pubTime":"2026-07-31 21:16","pubTimestamp":1785503760,"startTime":"0","endTime":"0","summary":"Guardant Health (GH) has an average rating of buy and mean price target of $191.09, according to analysts polled by FactSet.(MT Newswires covers equity, commodity and economic research from major bank","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"shareholding,express","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["GDOC","BK4588","BK4196","GNMX","GH","LU0320765992.SGD","BK4551","BK4535","PTH","FFOX","LFSC","LU0889565916.HKD","GNOM","HELX","LU0109394709.USD","BK4585","EKG"],"isVideo":false,"video":null,"gpt_icon":0}],"pageSize":20,"totalPage":10,"pageCount":7,"totalSize":199,"code":"91000000","status":"200"}]}}